4//SEC Filing
Kenney Richard T 4
Accession 0001641172-25-025100
CIK 0001106838other
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 4:48 PM ET
Size
11.3 KB
Accession
0001641172-25-025100
Insider Transaction Report
Form 4
Kenney Richard T
Chief Medical Officer
Transactions
- Award
Warrant
2025-06-30+86,505→ 86,505 totalExercise: $1.16From: 2025-06-30Exp: 2030-06-30→ Common Stock (86,505 underlying) - Award
Series 5 Preferred Stock
2025-07-14+200→ 200 totalExercise: $1.25From: 2025-07-14→ Common Stock (160,000 underlying) - Award
Warrant
2025-07-14+320,000→ 320,000 totalExercise: $1.25From: 2025-07-14Exp: 2030-07-14→ Common Stock (320,000 underlying)
Footnotes (3)
- [F1]On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of common stock, par value $0.0001 ("Common Stock") as partial consideration for a convertible note (the "Convertible Note") issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
- [F2]On July 14, 2025, the Reporting Person was issued warrants to purchase up to 320,000 shares of Common Stock upon the conversion in full of the Convertible Note. The warrants cannot be exercised to the extent that, after giving effect to such exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
- [F3]On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date.
Documents
Issuer
Sonnet BioTherapeutics Holdings, Inc.
CIK 0001106838
Entity typeother
Related Parties
1- filerCIK 0001606653
Filing Metadata
- Form type
- 4
- Filed
- Aug 20, 8:00 PM ET
- Accepted
- Aug 21, 4:48 PM ET
- Size
- 11.3 KB